A Ludwig Cancer Research study has identified a specific mode of fat uptake by immune cells within tumors that serves as a metabolic checkpoint against anti-cancer immune responses.
Ludwig Cancer Research is proud to support eight early-career scientists presenting their research at the conference this year through the AACR Scholar-in-Training Awards (SITA) program, contributing to the cost of their travel and attendance at the conference.
Ludwig Cancer Research released today the full scope of research to be presented by Ludwig-affiliated scientists at the American Association for Cancer Research (AACR) Annual Meeting 2025, which will be held online and in person in Chicago, from April 25 to April 30.
A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis remains just 8.5 months.
A Ludwig Cancer Research study has identified a key barrier to the efficacy of a promising combination of radiotherapy and immunotherapy for the treatment of brain metastases arising from breast cancer鈥攁nd in doing so uncovered approaches to overcoming that resistance.
Ludwig Cancer Research extends its congratulations to Ludwig Harvard鈥檚 Bradley Bernstein on his election as Fellow of the Academy of the American Association for Cancer Research.
Ludwig Cancer Research congratulates Douglas Hanahan, Ludwig Distinguished Scholar at the Lausanne Branch of the Ludwig Institute for Cancer Research, on his selection as recipient of the Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research.
Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells鈥攁 type of cancer immunotherapy鈥攖hat can be switched on to varying degrees of intensity and then switched off on demand with existing drugs.
Ludwig Cancer Research congratulates Ludwig Lausanne Director George Coukos on his election to the U.S. National Academy of Medicine (NAM). Among the highest honors issued to clinicians and scientists, membership in the Academy recognizes exceptional achievement and commitment to service in the fields of health and medicine.
Ludwig Cancer Research scientists have developed a full, start-to-finish computational pipeline that integrates multiple molecular and genetic analyses of tumors and the specific molecular targets of T cells and harnesses artificial intelligence algorithms to use its output to design personalized cancer vaccines for patients.
A Ludwig Cancer Research study has punctured a longstanding assumption about the source of the most common type of DNA mutation seen in the genome鈥攐ne that contributes to many genetic diseases, including cancer.
A Ludwig Cancer Research study has discovered that recurrent tumors of the aggressive brain cancer glioblastoma multiforme (GBM) grow out of the fibrous scars of malignant predecessors destroyed by interventions such as radiotherapy, surgery and immunotherapy.
A Ludwig Cancer Research study has identified a metabolic switch in the immune system鈥檚 T cells that is essential to the generation of memory T cells鈥攚hich confer lasting immunity to previously encountered pathogens鈥攁nd a T cell subtype found in tumors that drives anti-tumor responses during immunotherapy.
A novel immunotherapy approach developed by Ludwig Cancer Research scientists employs a two-pronged attack against solid tumors to boost the immune system鈥檚 ability to target and eliminate cancer cells.
Using artificial intelligence, Ludwig Cancer Research scientists have developed a powerful predictive model for identifying the most potent cancer killing immune cells for use in cancer immunotherapies.
A Ludwig Cancer Research study has discovered how a lipid molecule found at high levels within tumors undermines the anti-cancer immune response and compromises a recently approved immunotherapy known as adoptive cell therapy (ACT) using tumor infiltrating lymphocytes, or TIL-ACT.
Through an analysis of tumor samples collected over time from patients with advanced melanoma, a Ludwig Cancer Research study has identified a set of preexisting conditions in tumors that predict whether such patients are likely to respond to a personalized immunotherapy known as adoptive T cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL).
It is with great pleasure that we announce the appointment of Lydia Lynch as a full member of the Princeton Branch of the Ludwig Institute for Cancer Research.
A Ludwig Cancer Research study has generated a granular portrait of how the cellular and molecular components of the blood vessels that feed brain metastases of melanoma and lung and breast cancers differ from those of healthy brain tissue, illuminating how they help shape the internal environment of tumors to support cancer growth and immune evasion.
Ludwig Cancer Research announces its launch of the Ludwig Leadership Fellows Program, which aims to accelerate the careers of exceptional young scientists by helping them establish genuinely independent programs of research immediately after the completion of their graduate studies.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 麻豆传媒 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right